CN109303799A - 一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物及其制备方法 - Google Patents
一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物及其制备方法 Download PDFInfo
- Publication number
- CN109303799A CN109303799A CN201811503882.8A CN201811503882A CN109303799A CN 109303799 A CN109303799 A CN 109303799A CN 201811503882 A CN201811503882 A CN 201811503882A CN 109303799 A CN109303799 A CN 109303799A
- Authority
- CN
- China
- Prior art keywords
- lotus seeds
- leaching liquor
- shell extract
- lotus
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 240000002853 Nelumbo nucifera Species 0.000 title claims abstract description 117
- 235000006508 Nelumbo nucifera Nutrition 0.000 title claims abstract description 117
- 235000006510 Nelumbo pentapetala Nutrition 0.000 title claims abstract description 117
- 239000000284 extract Substances 0.000 title claims abstract description 74
- 230000000694 effects Effects 0.000 title claims abstract description 45
- 239000003112 inhibitor Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 37
- 238000000605 extraction Methods 0.000 title description 7
- 239000000843 powder Substances 0.000 claims abstract description 32
- 238000002137 ultrasound extraction Methods 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000003756 stirring Methods 0.000 claims abstract description 14
- 239000003960 organic solvent Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 49
- 238000002386 leaching Methods 0.000 claims description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 25
- 238000007654 immersion Methods 0.000 claims description 24
- 238000002390 rotary evaporation Methods 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 238000012545 processing Methods 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000006227 byproduct Substances 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 abstract description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 26
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 23
- 239000008103 glucose Substances 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 210000000813 small intestine Anatomy 0.000 description 12
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 11
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102400000471 Isomaltase Human genes 0.000 description 6
- 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical group O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000011073 invertase Nutrition 0.000 description 5
- 229960002632 acarbose Drugs 0.000 description 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 3
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102400000472 Sucrase Human genes 0.000 description 3
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 3
- 102000016679 alpha-Glucosidases Human genes 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000837 restrainer Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000679 brush border epithelial cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 125000003071 maltose group Chemical group 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种有ɑ‑葡萄糖苷酶抑制作用的莲子壳提取物,其特征在于,它是由下述方法制备:首先将莲子壳粉和亲水性有机溶剂混合搅匀,然后将所得物经超声浸提后干燥。本发明的优点:将农产品加工中的副产物进行处理,减少了对于环境的污染,化废为宝,获得一种可应用于功能性食品中的新的ɑ‑葡萄糖苷酶活性抑制成分。
Description
技术领域
本发明涉及一种食品提取物,特别涉及一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
随着人们生活水平的提高,饮食、环境等因素的影响使糖尿病的发病率极高。糖尿病是一种发病机制较复杂的内分泌系统疾病,多引起糖、脂肪和蛋白质代谢紊乱,以高血糖和尿糖为特征,与癌症和心脑血管病并称为世界三大健康杀手。α-葡萄糖苷酶是控制碳水化合物消化的一系列关键酶,包括麦芽糖酶、蔗糖酶、异麦芽糖酶、乳糖酶等酶类,主要分布于小肠上皮绒毛膜刷状沿上。在生理状态下,食物中的多糖,如淀粉经口腔唾液、胰淀粉酶消化成含少数葡萄糖分子的低聚糖,α-葡萄糖苷酶便在这些低聚糖的非还原末端切开α-1,4糖苷键,释放出葡萄糖,葡萄糖被小肠上皮吸收后进入血液循环,就成为血糖,因此,调控α-葡萄糖苷酶的活性可以调节餐后血糖值。α-葡萄糖苷酶抑制剂可逆性竞争抑制小肠粘膜刷状缘的α-葡萄糖苷酶,抑制淀粉、麦芽糖和蔗糖的分解,减缓葡萄糖的生成和吸收,从而降低餐后血糖峰值,减少血糖对胰腺的刺激,提高胰岛素的敏感性,保护胰腺的功能,有效预防并改善因高血糖引发起并发症的发生和发展。并且α-葡萄糖苷酶抑制剂在发挥作用的过程中,其并未影响机体对总碳水化合物的吸收,它只是降低碳水化合物的消化及小肠绒毛对葡萄糖的吸收速率。从而在一定程度上避免了糖尿病患者在治疗过程中出现的营养性能量缺乏症。
莲子壳是莲子加工生产中的副产物,当前我国每年莲壳的产量可达数万吨,因其质地坚硬,又不可食用,除将少量用作柴火的同时,只能将其大量的废弃于田间地头,任其自然腐败,对环境造成污染。经本发明人测定,这些废弃物中含有丰富的酚类物质,因此拟从中提取出一种具有α-葡萄糖苷酶抑制作用的活性成分。既有助于减少糖尿病的发生,又可以解决莲子产业副产物多的难题,充分利用自然资源,避免环境污染,拓宽莲产业开发应用空间,给莲产业带来附加效益。
发明内容
本发明的目的是提供一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物及其制备方法。
一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物,其中,它是由下述方法制备:首先将莲子壳粉和亲水性有机溶剂混合搅匀,然后将所得物经超声浸提后干燥。
制备本发明一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其中,依次包括以下步骤:
(1)按料液比1:6-14(g:mL)将莲子壳粉和体积比浓度为40-80%乙醇水溶液混合搅匀;
(2)将步骤(1)所得液体在室温条件下超声浸提20-40min,共浸提1-4次,离心,取得浸提液,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在35-60℃的条件下旋蒸浓缩,干燥即得一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
本发明一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其中,依次包括以下步骤:
(1)按料液比1:10(g:mL)将莲子壳粉和体积比浓度为60%乙醇水溶液混合搅匀;
(2)将步骤(1)所得液体在室温条件下超声浸提30min,共浸提2次,离心,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在40℃的条件下旋蒸浓缩,干燥即得一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
制备本发明莲子壳提取物的制备方法,其中,依次包括以下步骤:
(1)按料液比1:6-14(g:mL)将莲子壳粉和体积比浓度为40-80%甲醇水溶液混合搅匀;
(2)将步骤(1)所得液体在室温条件下超声浸提20-40min,共浸提1-4次,离心,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在35-60℃条件下旋蒸浓缩,干燥即得一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
本发明一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其中,依次包括以下步骤:
(1)按料液比1:10(g:mL)将莲子壳粉和体积比浓度为60%甲醇水溶液混合搅匀;
(2)将步骤(1)所得液体在室温条件下超声浸提30min,共浸提2次,离心,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在40℃的条件下旋蒸浓缩,干燥即得一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
制备本发明一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其中,依次包括以下步骤:
(1)按料液比1:6-14(g:mL)将莲子壳粉和体积比浓度为40-80%丙酮水溶液混合搅匀;
(2)将步骤(1)所得液体在室温条件下超声浸提20-40min,共浸提1-4次,离心,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在35-60℃的条件下旋蒸浓缩,干燥即得一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
本发明一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其中,依次包括以下步骤:
(1)按料液比1:10(g:mL)将莲子壳粉和体积比浓度为60%丙酮水溶液混合搅匀;
(2)将步骤(1)所得液体在,在室温条件下超声浸提30min,共浸提2次,离心,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在40℃条件下旋蒸浓缩,干燥即得一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
本发明一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物在制备抑制ɑ-葡萄糖苷酶药物中的应用。
本发明一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物在制备抑制ɑ-葡萄糖苷酶功能性食品中的应用。
本发明的优点:
将农产品加工中的副产物进行处理,减少了对于环境的污染,化废为宝,并在食品加工中获得一种新的可抑制ɑ-葡萄糖苷酶活性的功能成分。
本发明中所涉及到的乙醇水溶液、甲醇水溶液、丙酮水溶液的浓度均为体积比浓度。
附图说明
图1莲子壳提取物对α-葡萄糖苷酶活性的抑制效果图
具体实施方式
实施例1
莲子壳和乙醇混合制备莲子壳提取物的方法。
1.1制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:6(g:mL)将莲子壳粉100g和40%乙醇水溶液600mL混合搅匀,在室温条件下超声浸提20min,共浸提1次,离心浸提液,浸提液20℃旋蒸浓缩,干燥即得莲子壳提取物1.34g,低温冷藏。
1.2制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:10(g:mL)将莲子壳粉100g和60%乙醇水溶液1000mL混合搅匀,在室温条件下超声浸提30min,共浸提2次,离心,合并浸提液,浸提液40℃旋蒸浓缩,干燥即得莲子壳提取物1.58g,低温冷藏。
1.3制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:14(g:mL)将莲子壳粉100g和80%乙醇水溶液1400mL混合搅匀,在室温条件下超声浸提40min,共浸提4次,离心,合并浸提液,浸提液60℃旋蒸浓缩,干燥即得莲子壳提取物1.50g,低温冷藏。
实施例2
按照不同的比例将莲子壳粉和甲醇混合制备莲子壳提取物的方法
(1)制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:6(g:mL)将莲子壳粉100g和40%甲醇水溶液600mL混合搅匀,在室温条件下超声浸提20min,共浸提1次,离心浸提液,浸提液20℃旋蒸浓缩,干燥即得莲子壳提取物1.22g,低温冷藏。
(2)制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:10(g:mL)将莲子壳粉100g和体积比浓度为60%甲醇水溶液1000ml混合搅匀,在室温条件下超声浸提30min,离心,取得浸提液,共浸提2次,合并浸提液,浸提液40℃旋蒸浓缩,干燥即得莲子壳提取物1.39g,低温冷藏。
(3)制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:14(g:mL)将莲子壳粉100g和体积比浓度为80%甲醇水溶液1400ml混合搅匀,在室温条件下超声浸提40min,共浸提4次,离心,合并浸提液,浸提液60℃旋蒸浓缩,干燥即得莲子壳提取物1.48g,低温冷藏。
实施例3
莲子壳和去离子水混合制备莲子壳粉提取物的方法。
3.1制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:6(g:mL)将莲子壳粉100g和去离子水600mL混合搅匀,在室温条件下超声浸提20min,共浸提1次,离心浸提液,浸提液20℃旋蒸浓缩,干燥即得莲子壳提取物0.98g,低温冷藏。
3.2制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:10(g:mL)将莲子壳粉100g和去离子水1000mL混合搅匀,在室温条件下超声浸提30min,共浸提2次,离心,合并浸提液,浸提液40℃旋蒸浓缩,干燥即得莲子壳提取物1.06g,低温冷藏。
3.3制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:14(g:mL)将莲子壳粉100g和去离子水1400mL混合搅匀,在室温条件下超声浸提40min,共浸提4次,离心,合并浸提液,浸提液60℃旋蒸浓缩,干燥即得莲子壳提取物1.03g,低温冷藏。
实施例4
莲子壳和丙酮混合制备莲子壳提取物的方法。
4.1制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:6(g:mL)将莲子壳粉100g和40%丙酮水溶液600mL混合搅匀,在室温条件下超声浸提20min,共浸提1次,离心浸提液,浸提液20℃旋蒸浓缩,干燥即得莲子壳提取物1.36g,低温冷藏。
4.2制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:10(g:mL)将莲子壳粉100g和60%丙酮水溶液1000mL混合搅匀,在室温条件下超声浸提30min,共浸提2次,离心,合并浸提液,浸提液40℃旋蒸浓缩,干燥即得莲子壳提取物1.44g,低温冷藏。
4.3制备莲子壳提取物的制备方法,依次包括以下步骤:
按料液比1:14(g:mL)将莲子壳粉100g和80%丙酮水溶液1400mL混合搅匀,在室温条件下超声浸提40min,共浸提4次,离心,合并浸提液,浸提液60℃旋蒸浓缩,干燥即得莲子壳提取物1.49g,低温冷藏。
实施例5
莲子壳提取物对于抑制ɑ-葡萄糖苷酶活性的证明实验,采用的是实施例1的第2组所提取的物质进行的实验,通过实验证明,在同等条件下,实施例2-4所得到的成分可以达到和实施例1相同的效果。
材料和方法
1.1实验动物:雄性SPF级健康Wistar大鼠,体重150-160g,购自维通利华(许可证号SCXK(京)2012-0001)。
SPF级大小鼠维持饲料:碳水化合物64%,蛋白质21%,脂肪4%,纤维5%,购自北京科澳协力饲料有限公司。
1.2主要仪器与试剂
1.2.1仪器:JA2003C电子天平上海越平科学仪器有限公司;FE20实验室pH计梅特勒-托利多仪器(上海)有限公司;22PCO2435可见分光光度计上海棱光技术有限公司;DHG-9246A型电热恒温鼓风干燥箱上海精密实验设备有限公司;KH-100E型超声波清洗器昆山禾创超声仪器有限公司;HH-501超级恒温水浴(数显)常州国华电器有限公司;IKA RV10旋转蒸发仪;HITACCHI(R9A)高速冷冻离心机Himac CR 22GⅡ;手动玻璃匀浆器上海精科;ELx808酶标仪,美国Biotek公司;TOMOS 1-14微型离心机美国热电公司;等。
1.2.2原料和试剂:莲子壳,采自湖南湘潭,由三湘莲业贸易公司提供,干燥磨碎过60目筛,备用。NaH2PO4·2H20、Na2HPO4·12H20、天津市光复科技发展有限公司;HCl、无水乙醇、氯仿(分析纯)北京化工厂;葡萄糖测定试剂盒,上海荣盛生物技术有限公司;麦芽糖、异麦芽糖、蔗糖,天津市光复科技有限公司;拜唐苹拜耳医药保健有限公司等。
1.3试验方法
1.3.1大鼠α-葡萄糖苷酶的制备
乙醚麻醉大鼠,解剖后立即取出小肠上端部分,用冷的生理盐水冲洗干净,剪开小肠,平铺内表面于冰台上,用干净载玻片刮取小肠内表面,将刮取物加入冷的10倍量的pH6.8PBS缓冲液,用玻璃匀浆器匀浆,以上操作均在冰浴上进行。将匀浆液在4℃、10000/min离心25min,取上清液分装,-40℃下贮存备用。
1.3.2大鼠α-葡萄糖苷酶活性的测定
分别以麦芽糖、异麦芽糖和蔗糖为底物,测定小肠α-葡萄糖苷酶的活性,具体步骤如下:取0.2mL制备的上清酶液,加入0.7mL pH6.8的PBS缓冲液,37℃水浴10min后,加入0.5mol/L的底物溶液(麦芽糖或异麦芽糖或蔗糖)0.1mL,混匀,37℃反应20min后,加入0.1mol/L的Na2CO3溶液0.5mL终止反应;取上述反应液10μl,加入1mL葡萄糖测定试剂,37℃水浴反应15min,测定505nm下的吸光度;做三组平行实验,取平均值。以葡萄糖的生成量计算α-葡萄糖苷酶的活性,即在37℃pH6.8的条件下,1L溶液中每分钟生成1μmol葡萄糖定义为1个酶活力单位。
1.3.3莲子壳提取物对体外大鼠α-葡萄糖苷酶的抑制作用测定
将莲子壳提取物按浓度梯度分别配制成0、0.625、2.5、5、12.5、25mg/mL的溶液,取上述样品液各0.2mL,加入pH6.8 PBS 0.2mL和0.5mol/L麦芽糖溶液0.2mL,混匀,加入0.1mLα-葡萄糖苷酶液,漩涡混匀,37℃水浴反应20min后,加入0.7mL 0.1mol/L Na2CO3终止反应;取上述反应液10μl,加入1mL葡萄糖测定试剂,37℃反应15min,于505nm下测定吸光度;同时设置阳性对照阿卡波糖组(阿卡波糖源自拜耳医药保健有限公司生产的拜唐苹片剂,每片含有50mg阿卡波糖,本实验将拜唐苹片溶解于水中,配制阿卡波糖浓度分别为0、0.625、2.5、5、12.5、25mg/mL的溶液)进行比较对照。然后分别以异麦芽糖和蔗糖为底物,重复以上步骤进行测定。每组实验平行测定三次,取平均值,按以下公式计算莲子壳提取物对小肠α-葡萄糖苷酶的抑制率:
1.3.4口服莲子壳提取物对大鼠体内α-葡萄糖苷酶活性的影响
取20只Wistar大鼠,适应环境饲养3天,饲喂SPF级大小鼠维持饲料,自由饮水、觅食,然后依据随机分成对照组和试验组,每组各10只。除自由摄取维持饲料和饮用水外,实验期内对照组大鼠每天灌胃蒸馏水一次,实验组大鼠每天按时灌胃受试样品一次(100mg/kg·bw/天),两周后宰杀大鼠,以1.3.1和1.3.2所描述方法,测定两组大鼠体内的α-葡萄糖苷酶活性。本实施例中所述的给予受试物是实施例一中所得的莲子壳提取物。
1.4数据处理:使用Excel软件进行数据处理、分析和作图,使用SPSS19.0软件,采用独立样本t检验进行显著性分析。
2实验结果
2.1大鼠α-葡萄糖苷酶活性的测定结果
表1 大鼠小肠α-葡萄糖苷酶活性
α-葡萄糖苷酶是一类能从含有α-糖苷键底物的非还原端催化水解葡萄糖基的酶的总称,由唾液和胰液中α-淀粉酶及小肠刷状缘上皮细胞上的麦芽糖酶、异麦芽糖酶和蔗糖酶等组成。如表1所示,大鼠小肠α-葡萄糖苷酶中麦芽糖酶活性最高,异麦芽糖酶活性其次,蔗糖酶活性最低。
2.2莲子壳提取物对体外α-葡萄糖苷酶活性的抑制效果
如图1所示,莲子壳提取物在0-25mg/mL范围内随着浓度的增加,对α-葡萄糖苷酶活性的抑制率不断增加,其中对麦芽糖酶活性的抑制效果最强,最高抑制率可达87.9%;对异麦芽糖酶活性的抑制效果适中,对蔗糖酶活性的抑制效果稍弱。并且在12.5-25mg/mL浓度范围内,莲子壳提取物对麦芽糖酶、异麦芽糖酶、蔗糖酶等α-葡萄糖苷酶的活性抑制效果均强于阳性对照阿卡波糖。
2.3口服莲子壳提取物对大鼠体内α-葡萄糖苷酶活性的影响
表2 口服莲子壳提取物两周后大鼠体内α-葡萄糖苷酶活性
(均值±标准偏差,n=10,U/mL)
注:采用SPSS19.0软件独立样本t-检验进行显著性分析,与对照组比较,*表示P<0.05,**表示P<0.01。
如表2所示,莲子壳提取物经口饲喂普通Wistar大鼠两周后,大鼠小肠上皮绒毛膜刷状缘沿上的α-葡萄糖苷酶活性明显被抑制,其中蔗糖酶活性显著降低(P<0.05),麦芽糖酶和异麦芽糖酶活性极显著降低(P<0.01),与上述体外实验的结果相一致。由此可见,莲子壳提取物能有效调节α-葡萄糖苷酶活性,抑制淀粉、麦芽糖和蔗糖的分解,减缓葡萄糖的生成和吸收,从而降低餐后血糖峰值,预防并改善因高血糖引发起并发症的发生和发展。
Claims (9)
1.一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物,其特征在于,它是由下述方法制备:首先将莲子壳粉和亲水性有机溶剂混合搅匀,然后将所得物经超声浸提后干燥。
2.制备如权利要求1所述的一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其特征在于,依次包括以下步骤:
(1)莲子壳晒干碾磨成粉,过60目筛,按料液比1:6-14(g:mL)将莲子壳粉和体积比浓度为40-80%乙醇水溶液混合搅匀;
(2)将步骤(1)所得液体在室温条件下超声浸提20-40min,离心,取得浸提液,共浸离心提1-4次,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在35-60℃的条件下旋蒸浓缩,干燥即得一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
3.如权利要求2所述一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其特征在于,依次包括以下步骤:
(1)按料液比1:10(g:mL)将莲子壳粉和体积比浓度为60%乙醇水溶液混合搅匀;
(2)将步骤(1)所得液体在室温条件下超声浸提30min,离心,取得浸提液,共浸提离心2次,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在40℃的条件下旋蒸浓缩,干燥即得一种莲子壳粉提取物。
4.制备如权利要求1所述的一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其特征在于,依次包括以下步骤:
(1)按料液比1:6-14(g:mL)将莲子壳粉和体积比浓度为40-80%甲醇水溶液混合搅匀;
(2)将步骤(1)所得液体在室温条件下超声浸提20-40min,离心,取得浸提液,共浸提离心1-4次,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在35-60℃条件下旋蒸浓缩,干燥即得一种莲子壳粉提取物。
5.如权利要求4所述一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其特征在于,依次包括以下步骤:
(1)按料液比1:10(g:mL)将莲子壳粉和体积比浓度为60%甲醇水溶液混合搅匀;
(2)将步骤(1)所得液体在室温条件下超声浸提30min,离心,取得浸提液,共浸提2次,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在40℃的条件下旋蒸浓缩,干燥即得一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
6.制备如权利要求1所述的一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其特征在于,依次包括以下步骤:
(1)按料液比1:6-14(g:mL)将莲子壳粉和体积比浓度为40-80%丙酮水溶液混合搅匀;
(2)将步骤(1)所得液体在室温条件下超声浸提20-40min,共浸提1-4次,离心,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在35-60℃的条件下旋蒸浓缩,干燥即得一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
7.如权利要求6所述一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物的制备方法,其特征在于,依次包括以下步骤:
(1)按料液比1:10(g:mL)将莲子壳粉和体积比浓度为60%丙酮水溶液混合搅匀;
(2)将步骤(1)所得液体在,在室温条件下超声浸提30min,离心,取得浸提液,共浸提2次,将每次所得的浸提液合并;
(3)将步骤(2)所得液体在40℃条件下旋蒸浓缩,干燥即得一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物。
8.如权利要求1所述的一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物在制备抑制ɑ-葡萄糖苷酶药物中的应用。
9.如权利要求1所述的一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物在制备抑制ɑ-葡萄糖苷酶功能性食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811503882.8A CN109303799A (zh) | 2018-12-10 | 2018-12-10 | 一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811503882.8A CN109303799A (zh) | 2018-12-10 | 2018-12-10 | 一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109303799A true CN109303799A (zh) | 2019-02-05 |
Family
ID=65223526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811503882.8A Withdrawn CN109303799A (zh) | 2018-12-10 | 2018-12-10 | 一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109303799A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021054784A (ja) * | 2019-09-26 | 2021-04-08 | ティーシーアイ カンパニー リミテッド | 細胞傷害を防止するための蓮の実の殻抽出物及びその用途 |
CN117357576A (zh) * | 2023-11-07 | 2024-01-09 | 北京工商大学 | 具有降血糖功效的莲子壳多酚提取物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103045546A (zh) * | 2012-12-30 | 2013-04-17 | 湘潭大学 | 一种以莲子壳为原料生产饲用复合酶的方法 |
-
2018
- 2018-12-10 CN CN201811503882.8A patent/CN109303799A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103045546A (zh) * | 2012-12-30 | 2013-04-17 | 湘潭大学 | 一种以莲子壳为原料生产饲用复合酶的方法 |
Non-Patent Citations (1)
Title |
---|
张露等: "5种莲副产物中活性成分及其抗氧化、α-葡萄糖苷酶抑制活性比较", 《食品科学》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021054784A (ja) * | 2019-09-26 | 2021-04-08 | ティーシーアイ カンパニー リミテッド | 細胞傷害を防止するための蓮の実の殻抽出物及びその用途 |
CN117357576A (zh) * | 2023-11-07 | 2024-01-09 | 北京工商大学 | 具有降血糖功效的莲子壳多酚提取物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ortiz-Andrade et al. | α-Glucosidase inhibitory activity of the methanolic extract from Tournefortia hartwegiana: an anti-hyperglycemic agent | |
Yue et al. | Cucurbitane triterpenoids from Momordica charantia L. and their inhibitory activity against α-glucosidase, α-amylase and protein tyrosine phosphatase 1B (PTP1B) | |
Ortiz‐Andrade et al. | Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra‐pancreatic glucose regulation | |
Tian et al. | Cardiac glycosides from the seeds of Thevetia peruviana | |
Jiang et al. | Biologically active triterpenoid saponins from Acanthopanax senticosus | |
Yang et al. | Chemical composition and antioxidant activity of an acidic polysaccharide extracted from Cucurbita moschata Duchesne ex Poiret | |
Motaal et al. | Aldose reductase inhibition of a saponin-rich fraction and new furostanol saponin derivatives from Balanites aegyptiaca | |
Geethalakshmi et al. | α-Amylase inhibitory activity of Trianthema decandra L | |
Liang et al. | Digestibility of squash polysaccharide under simulated salivary, gastric and intestinal conditions and its impact on short-chain fatty acid production in type-2 diabetic rats | |
Chen et al. | Structural elucidation of a novel polysaccharide from Pseudostellaria heterophylla and stimulating glucose uptake in cells and distributing in rats by oral | |
CN109303799A (zh) | 一种有ɑ-葡萄糖苷酶抑制作用的莲子壳提取物及其制备方法 | |
Aruan et al. | Phytochemical screening and antidiabetic activity of N-hexane, ethyl acetate and water extract from durian leaves (Durio zibethinus L.) | |
Malik et al. | Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment | |
Berrué et al. | Isolation of steroidal glycosides from the Caribbean sponge Pandaros acanthifolium | |
CN101422465A (zh) | 熊果酸及含其的植物提取物的应用 | |
Miller et al. | Critical assessment of in vitro screening of α-glucosidase inhibitors from plants with acarbose as a reference standard | |
Ren et al. | Structural characterization and tartary buckwheat polysaccharides alleviate insulin resistance by suppressing SOCS3-induced IRS1 protein degradation | |
Saeidnia et al. | Chemical constituents of Swertia longifolia Boiss. with α-amylase inhibitory activity | |
Verma et al. | A triterpene glochidon from Phyllanthus debilis: Isolation, computational studies, and antidiabetic activity evaluation | |
Gao et al. | Ginsenosides, ingredients of the root of Panax ginseng, are not substrates but inhibitors of sodium-glucose transporter 1 | |
Tonsic et al. | An in vivo approach to the reported effects of phenolic acids and flavonoids on the pancreatic α-amylase activity | |
Pollo et al. | A new polyacetylene glucoside from Vernonia scorpioides and its potential antihyperglycemic effect | |
CN109394840A (zh) | 一种有α-葡萄糖苷酶抑制作用的莲子红衣提取物及其制备方法 | |
Alam et al. | Anthraquinone-type inhibitor of α-glucosidase enhances glucose uptake by activating an insulin-like signaling pathway in C2C12 myotubes | |
Priya et al. | Analysis of in vitro and in silico anti-hyperglycaemic action of bioflavonoids isolated from different citrus peels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190205 |